Thus, although AKR1B10 may be a molecular marker reflecting the progression of NAFLD ranging from steatohepatitis to HCC, further clinical studies are required to standardize the measurement of plasma/serum AKR1B10. The gene discussed is AKR1B10; the disease is metabolic dysfunction-associated steatotic liver disease.